Australian government expands subsidies for abemaciclib (Verzenio) breast cancer treatment, benefiting 2,400 patients.

The Australian government is expanding subsidies for abemaciclib (Verzenio), a treatment that could prevent the spread of early-stage breast cancer. This move benefits 2,400 Australians at risk of recurrence, with the drug costing as little as $7.70. Natalie Fraser, a 54-year-old Sydney woman, was among those who benefited from the treatment after her breast cancer returned in her lymph nodes.